Cover Image

市場進入的課題:HIV (歐盟5國)

Market Access Impact: HIV (EU5)

出版商 FirstWord 商品編碼 358490
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
市場進入的課題:HIV (歐盟5國) Market Access Impact: HIV (EU5)
出版日期: 2016年04月01日 內容資訊: 英文

本報告由以歐盟5國 (法國·義大利·德國·西班牙·英國) 150名感染疾病專門醫生為對象所進行的HIV治療藥的處方趨勢調查結果,得出給付,價格等主要8品牌的市場進入障礙·影響因素之比較分析及個別分析,並彙整其對市場佔有率的影響等資訊。


  • 各種障礙對打入市場的影響
    • 醫生最大量開處方的品牌為何?
    • 受各種障礙影響的處方箋數為何?
    • 哪個障礙最影響大?
  • 障礙對各品牌的影響
    • 醫生對各品牌的處方數為何?不打算再開處方的數為何?
    • 醫生不開處方的理由為何?替代其開處方的藥物為何?
    • 被競爭品牌奪走的佔有率有多少?


  • Celsentri
  • Evotaz
  • Intelence
  • Isentress
  • Stribild
  • Triumeq
  • Truvada
  • Viread
Product Code: 596200650

Can prescription barriers help the 2nd and 3rd place HIV brands catch up to the runaway market leader?

In the European HIV treatment market, the leading brand is comfortably ahead-but can market barriers help either of the 3rd-place contenders move up to the #2 spot.

Market Access Impact: HIV shows you which brands you're losing share to, which brands you're taking it from, and why.

Market Access Impact: HIV explores how cost concerns and other barriers affect market share for 8 major HIV treatments: Celsentri, Evotaz, Intelence, Isentress, Stribild, Triumeq, Truvada, and Viread.

You'll find out which brands your brand is losing share to, which ones you're taking it from, and why-information you can use to compete more effectively.

Get Answers to Key Questions about HIV Drug Brands

  • Celsentri (maraviroc; ViiV Healthcare) : Which two leading FDCs does Celsentri take the most share from?
  • Evotaz (atazanavir/cobicistat; BMS) : Which barrier do more than twice as many doctors experience with Evotaz than any other brand?
  • Intelence (etravirine; Janssen Therapeutics) : Is limited availability or patient preference a bigger issue for doctors prescribing Intelence?
  • Isentress (raltegravir; Merck & Co.) : Isentress and Stribild are prescribed equally. Which brand has better awareness among doctors?
  • Stribild (elvitegravir/emtricitabine/tenofovir disoproxil fumarate/cobicistat; Gilead) : Which market barrier costs Stribild more than twice as much share as any other?
  • Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare) : Nearly half of Triumeq's share loss is to one other brand. Which one?
  • Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead) : Which barrier is responsible for over a third of Truvada's net share gain?
  • Viread (tenofovir disoproxil fumarate; Gilead) : Viread sees a net share gain from all but two surveyed brands. Which two?

Top Takeaways

  • Clear winners and losers: The two most prescribed brands have the biggest market share and barrier-related gains, while the two least prescribed brands have the smallest share and the greatest losses.
  • Half of brands benefit from barriers: But the two biggest winners see significantly bigger gains than the other two brands.
  • Brand awareness is high: With one exception, at least 97% of doctors surveyed are aware of any given brand.
  • Barrier effect is uneven: The number of doctors who experience the top 2 market barriers varies greatly from brand to brand.
  • No clear advantage for FDCs vs. monotherapies: Of the four most prescribed brands, two are fixed-dose products while the other two are monotherapies.
  • Cost and labelling issues have the greatest impact: Barriers related to guidelines and patient type restrictions affect more prescriptions than any others.
  • Barrier effect significant for "other" brands: Taken together, "other" brands have a greater market share than 3/4 of the surveyed brands, and see the third biggest net gain due to barriers.

Exploring Market Access Issues

Market Access Impact: HIV explores key issues affecting HIV drug manufacturers. You'll learn:

How barriers affect market access:

  • What brands do doctors prescribe the most?
  • How many prescriptions do barriers affect?
  • Which barriers have the biggest effect?

How barriers affect your brand:

  • How many doctors prescribe your brand? How many don't, but would consider it?
  • Why don't doctors prescribe your brand? What do they prescribe instead?
  • Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge

We surveyed 150 infectious disease specialists - 30 from each EU5 country (France, Italy, Germany, Spain, UK) - chosen from the largest community of validated physicians in the world.

All respondents have:

  • Been practicing for 2+ years
  • Prescribed at least one of the listed products
  • Seen at least 5 patients with melanoma in total in the last month

We conducted the survey between March 2nd and 9th, 2016.

Back to Top